Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit

Yu Wang1,2, Eric C Abenojar1, Jing Wang1

  • 1Department of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.

The Prostate
|February 15, 2022
PubMed
Abstract

Insights

Researchers developed a new orthotopic prostate cancer (PCa) rabbit model for preclinical testing. This model offers a clinically relevant alternative for evaluating new diagnostic and therapeutic compounds.

Area of Science:

  • Oncology
  • Animal Models
  • Medical Imaging

Background:

  • Existing mouse and rat prostate cancer (PCa) models have limitations in size and anatomical accessibility.
  • The canine PCa model is effective but costly and sparsely available.
  • Rabbits offer a phylogenetically closer, anatomically similar, and larger alternative for preclinical studies.

Purpose of the Study:

  • To develop an orthotopic human prostate tumor model in an immunosuppressed rabbit.
  • To evaluate the feasibility and clinical relevance of this new animal model for preclinical interventions.

Main Methods:

  • Human PCa cells were injected into the prostates of immunosuppressed rabbits via laparotomy or ultrasound (US)-guided injection.
  • Tumor growth was monitored using US and magnetic resonance imaging (MRI).
  • Contrast-enhanced ultrasound (CEUS) and ex vivo analyses were used to characterize tumors and PSMA expression.

Main Results:

  • The orthotopic PCa rabbit model was successfully established in 14 out of 20 rabbits.
  • US-guided injection was superior to laparotomy due to faster rabbit recovery.
  • Tumors showed characteristic imaging features on CEUS and MRI and expressed PSMA.

Conclusions:

  • An orthotopic prostate cancer rabbit model was established using percutaneous US-guided tumor cell inoculation.
  • This model provides a clinically relevant platform for assessing preclinical diagnostic and therapeutic compounds.

Related Concept Videos